Navigation Links
Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Date:9/5/2013

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas.  The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting techniques; and (iii) First-in-man study findings of its trypsin-liable extended-release hydromorphone prodrug.

(Logo:  http://photos.prnewswire.com/prnh/20130729/SF54809LOGO)

Every year in the United States prescription opioid abuse is responsible for tens of thousands of deaths and tens of billions of dollars in increased health care costs.  Wes Sterman, President and CEO of Signature Therapeutics, commented, "We believe that our prodrug technology approach creating abuse-deterrent opioid drugs has the potential to greatly impact the public health crisis of prescription drug abuse."

About The Opioid Abuse Challenge

The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States. Despite efforts to develop opioid drug formulations that are resistant to tampering, abusers will soon match the advances in pill/tablet formulation technology with new ways to abuse these drugs.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.

About Signature Therapeutics

Signature Therapeutics, Inc. is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders.

Signature Therapeutics Contact:

Carey DeRafael

email: cderafael@signaturerx.com
phone: 650-331-4006
website: http://www.signaturerx.com



'/>"/>
SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Senator Shares Insight on Florida Physician Dispensing Legislation as First Guest of Progressive Medicals New SignatureSeries
2. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
3. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
4. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured to have ... UK’s most prestigious award for business success. The company has been recognized ... has grown by a total of 400% over the last six years. , ...
(Date:4/21/2017)... ... 21, 2017 , ... Providing for loved ones before one’s passing is of ... to even begin. “Now more than ever there are some questions that are far ... your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa ...
(Date:4/21/2017)... ... ... Westside Dental Associates and its owner, Dr. Les Latner, have ... Latner has become one of the Los Angeles area’s premier dentists. “It’s been an ... their dental needs,” said Dr. Latner, who was recently named Chairperson of the ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is urged to give back ... trees and look forward to a better future. However, supporting the environment should be ... air quality can be two to five times more polluted than outdoor air, reports ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, ... between the Obamacare program that most Republicans love to hate and Texas Agriculture ... kill hogs. , Like Obamacare, the Miller program centers upon a federal ...
Breaking Medicine News(10 mins):